Investigators say that treating patients is more intense during the first stages of the illness, they can get better results and can also find a cure for this illness.
Daniela Osorio Rivera
Agencia Latina de Noticias Medicina y Salud Pública
In an article in the Impressive Journal of Medicine and Public Health (MSP), by Dr. Joel López Figueroa, oncologist at the Auxilio Mutuo Hospital’s Cancer Center, which indicates that some patients with Multiple Multiple Inflammation present. For this reason the time-consuming detection is important to know also the possibilities that the great advances in treatment taken to treat it are taken.
Dr. López Figueroa details that multiple myeloma many times are accidentally diagnosed by accident to find proteins raised in blood in the urine. Without embarrassment, while not holding traditional symptoms, it is likely that diagnostics is more difficult. This condition is characterized by the infiltration of plasmatic cells into the oceanic medium, which produces a monoclonal protein in its acid and orange also known as “monoclonal pico”.
The most important evaluation after obtaining the diagnosis of multiple myeloma (MM) is the risk assessment. In this way, the specialist can appreciate the progressive pain of myeloma.
Dr. López Figueroa indicates that in order to treat this disorder he developed various risk assessment models. The two most famous sons: the model of the Clinic Mayo and the Spanish model. The Mayo Clinic’s model is based on the infiltration of plasmatic cells into the oceanic medium, the M protein component and the proportion of live cadences. While the Spanish model uses aberrant plasmatic cells in immunophenotype immunotherapy.
Treatment:
Investigators say that in treating the most intense patients in the early stages of the illness, they can obtain the best results and including being able to find a cure for this illness.
El Dr. López Figueroa explained that at present there is only one therapy approved for the treatment of patients with multiple myeloma. Preventive therapy began studying in 2013 by a group of Spanish investigators. The specialist demonstrates that the patients who have multiple indolent risk of high altitude, receiving the combination of lenidomide with dexamethasone may reduce the progression of this disease. The specialist explained that these results were confirmed in another study that evaluated the use of lenalidomide, as a prevention strategy in patients with multiple indolent medium interval or alto.
This strategy demonstrates a 78% risk reduction in all patients and 90% in high-risk patients specifically, the specialist explained.
Based on these results, it is possible to use lenalidomide, as a debilitating agent or in combination with dexamethasone for patients with indigestion that indicates the doctor.